IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation

Journal of Immunology

Volumn 185, Issue 8, 2010, Pages 4912-4920

  Zaki, Mohammad Hasan ^a   Vogel, Peter ^a   Body Malapel, Mathilde ^b   Lamkanfi, Mohamed ^c,d   Kanneganti, Thirumala Devi ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITÉ DE LILLE   (France)

^c GHENT UNIVERSITY   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; CRYOPYRIN; DEXTRAN SULFATE; EFFECTOR CASPASE; GAMMA INTERFERON; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; STAT1 PROTEIN; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; COLITIS; COLORECTAL TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL TRANSFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INTERLEUKIN-18; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78049488908     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002046     Document Type: Article

References (59)

1. Choi, P. M., and M. P. Zelig. 1994. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35:950-954.
2. Eaden, J. A., K. R. Abrams, and J. F. Mayberry. 2001. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48:526-535.
3. Ekbom, A., C. Helmick, M. Zack, and H. O. Adami. 1990. Ulcerative colitis and colorectal cancer: a population-based study. N. Engl. J. Med. 323:1228-1233.
4. Itzkowitz, S. H., and X. Yio. 2004. Inflammation and cancer, IV: colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G7-G17.
5. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420:860-867.
6. Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140:883-899.
7. Krelin, Y., E. Voronov, S. Dotan, M. Elkabets, E. Reich, M. Fogel, M. Huszar, Y. Iwakura, S. Segal, C. A. Dinarello, and R. N. Apte. 2007. Interleukin-1bdriven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67:1062-1071.
8. Tamura, K., Y. Fukuda, H. Sashio, N. Takeda, H. Bamba, T. Kosaka, S. Fukui, K. Sawada, K. Tamura, M. Satomi, et al. 2002. IL18 polymorphism is associated with an increased risk of Crohn's disease. J. Gastroenterol. 37 (Suppl. 14):111-116.
9. Greten, F. R., L. Eckmann, T. F. Greten, J. M. Park, Z. W. Li, L. J. Egan, M. F. Kagnoff, and M. Karin. 2004. IKKb links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285-296.
10. Karin, M. 2006. Nuclear factor-kB in cancer development and progression. Nature 441:431-436.
11. Kanneganti, T. D., M. Lamkanfi, and G. Núñez. 2007. Intracellular NOD-like receptors in host defense and disease. Immunity 27:549-559.
12. Kopp, E., and R. Medzhitov. 2003. Recognition of microbial infection by Tolllike receptors. Curr. Opin. Immunol. 15:396-401.
13. Kawai, T., and S. Akira. 2007. Signaling to NF-kB by Toll-like receptors. Trends Mol. Med. 13:460-469.
14. Rhee, S. H., E. Im, and C. Pothoulakis. 2008. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135:518-528.
15. Kanneganti, T. D., N. Ozören, M. Body-Malapel, A. Amer, J. H. Park, L. Franchi, J. Whitfield, W. Barchet, M. Colonna, P. Vandenabeele, et al. 2006. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233-236.
16. Martinon, F., K. Burns, and J. Tschopp. 2002. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-b. Mol. Cell 10:417-426.
17. Ghayur, T., S. Banerjee, M. Hugunin, D. Butler, L. Herzog, A. Carter, L. Quintal, L. Sekut, R. Talanian, M. Paskind, et al. 1997. Caspase-1 processes IFN-g-inducing factor and regulates LPS-induced IFN-g production. Nature 386:619-623.
18. Kuida, K., J. A. Lippke, G. Ku, M. W. Harding, D. J. Livingston, M. S. Su, and R. A. Flavell. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1b converting enzyme. Science 267:2000-2003.
19. Nold-Petry, C. A., M. F. Nold, J. W. Nielsen, A. Bustamante, J. A. Zepp, K. A. Storm, J. W. Hong, S. H. Kim, and C. A. Dinarello. 2009. Increased cytokine production in interleukin-18 receptor alpha-deficient cells is associated with dysregulation of suppressors of cytokine signaling. J. Biol. Chem. 284:25900-25911.
20. Kalina, U., D. Kauschat, N. Koyama, H. Nuernberger, K. Ballas, S. Koschmieder, G. Bug, W. K. Hofmann, D. Hoelzer, and O. G. Ottmann. 2000. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-g production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. J. Immunol. 165:1307-1313.
21. Takeda, K., H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, and S. Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8:383-390.
22. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-g production by T cells. Nature 378:88-91.
23. Horwood, N. J., N. Udagawa, J. Elliott, D. Grail, H. Okamura, M. Kurimoto, A. R. Dunn, T. Martin, and M. T. Gillespie. 1998. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colonystimulating factor. J. Clin. Invest. 101:595-603.
24. Maxwell, J. R., R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella. 2006. IL-18 bridges innate and adaptive immunity through IFN-g and the CD134 pathway. J. Immunol. 177:234-245.
25. Chen, G. Y., M. H. Shaw, G. Redondo, and G. Núñez. 2008. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 68:10060-10067.
26. Villani, A. C., M. Lemire, G. Fortin, E. Louis, M. S. Silverberg, C. Collette, N. Baba, C. Libioulle, J. Belaiche, A. Bitton, et al. 2009. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat. Genet. 41:71-76.
27. Dupaul-Chicoine, J., G. Yeretssian, K. Doiron, K. S. Bergstrom, C. R. McIntire, P. M. LeBlanc, C. Meunier, C. Turbide, P. Gros, N. Beauchemin, et al. 2010. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32:367-378.
28. Allen, I. C., E. M. TeKippe, R. M. Woodford, J. M. Uronis, E. K. Holl, A. B. Rogers, H. H. Herfarth, C. Jobin, and J. P. Ting. 2010. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitisassociated cancer. J. Exp. Med. 207:1045-1056.
29. Zaki, M. H., K. L. Boyd, P. Vogel, M. B. Kastan, M. Lamkanfi, and T. D. Kanneganti. 2010. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32:379-391.
30. Ippagunta, S. K., D. D. Brand, J. Luo, K. L. Boyd, C. Calabrese, R. Stienstra, F. L. Van de Veerdonk, M. G. Netea, L. A. Joosten, M. Lamkanfi, and T. D. Kanneganti. 2010. Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. J. Biol. Chem. 285:12454-12462.
31. Okayasu, I., T. Ohkusa, K. Kajiura, J. Kanno, and S. Sakamoto. 1996. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39:87-92.
32. Lamkanfi, M., and T. D. Kanneganti. 2010. Nlrp3: an immune sensor of cellular stress and infection. Int. J. Biochem. Cell Biol. 42:792-795.
33. Greenhough, A., H. J. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi. 2009. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377-386.
34. Dighe, A. S., E. Richards, L. J. Old, and R. D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNg receptors. Immunity 1:447-456.
35. Lesinski, G. B., B. Badgwell, J. Zimmerer, T. Crespin, Y. Hu, G. Abood, and W. E. Carson, III. 2004. IL-12 pretreatments enhance IFN-a-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-a in a murine model of malignant melanoma. J. Immunol. 172:7368-7376.
36. Sato, T., C. Selleri, N. S. Young, and J. P. Maciejewski. 1997. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-g due to phosphorylation of Stat1 and Stat3. Blood 90:4749-4758.
37. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNg and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111.
38. Street, S. E., J. A. Trapani, D. MacGregor, and M. J. Smyth. 2002. Suppression of lymphoma and epithelial malignancies effected by interferon g. J. Exp. Med. 196:129-134.
39. Badgwell, B., G. B. Lesinski, C. Magro, G. Abood, A. Skaf, and W. Carson, III. 2004. The antitumor effects of interferon-a are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J. Surg. Res. 116:129-136.
40. Stephanou, A., and D. S. Latchman. 2003. STAT-1: a novel regulator of apoptosis. Int. J. Exp. Pathol. 84:239-244.
41. Hugot, J. P., M. Chamaillard, H. Zouali, S. Lesage, J. P. Cézard, J. Belaiche, S. Almer, C. Tysk, C. A. O'Morain, M. Gassull, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603.
42. Ogura, Y., D. K. Bonen, N. Inohara, D. L. Nicolae, F. F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliuskas, R. H. Duerr, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606.
43. Munkholm, P. 2003. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 (Suppl. 2):1-5.
44. Roberts, R. L., R. B. Gearry, M. D. Allington, H. R. Morrin, B. A. Robinson, and F. A. Frizelle. 2006. Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Res. 66:2532-2535.
45. Anthony, K. 2010. Immunology: the inflammasome protects? Nat. Rev. Cancer 10:383.
46. Micallef, M. J., T. Tanimoto, K. Kohno, M. Ikeda, and M. Kurimoto. 1997. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. 57:4557-4563.
47. Micallef, M. J., K. Yoshida, S. Kawai, T. Hanaya, K. Kohno, S. Arai, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, and M. Kurimoto. 1997. In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43:361-367.
48. Osaki, T., W. Hashimoto, A. Gambotto, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1999. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18). Gene Ther. 6:808-815.
49. Osaki, T., J. M. Péron, Q. Cai, H. Okamura, P. D. Robbins, M. Kurimoto, M. T. Lotze, and H. Tahara. 1998. IFN-γ-inducing factor/IL-18 administration mediates IFN-γ-and IL-12-independent antitumor effects. J. Immunol. 160:1742-1749.
50. Cao, E., X. Zang, U. A. Ramagopal, A. Mukhopadhaya, A. Fedorov, E. Fedorov, W. D. Zencheck, J. W. Lary, J. L. Cole, H. Deng, et al. 2007. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligandbinding surface. Immunity 26:311-321.
51. Coughlin, C. M., K. E. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. E. Chang, C. A. Hunter, J. C. Fox, G. Trinchieri, and W. M. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101:1441-1452.
52. Hegardt, P., B. Widegren, L. Li, B. Sjögren, C. Kjellman, I. Sur, and H. O. Sjögren. 2001. Nitric oxide synthase inhibitor and IL-18 enhance the antitumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol. Immunother. 50:491-501.
53. Reuter, B. K., and T. T. Pizarro. 2004. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur. J. Immunol. 34:2347-2355.
54. Radtke, F., and H. Clevers. 2005. Self-renewal and cancer of the gut: two sides of a coin. Science 307:1904-1909.
55. Sheikh, S. Z., K. Matsuoka, T. Kobayashi, F. Li, T. Rubinas, and S. E. Plevy. 2010. Cutting edge: IFN-γ is a negative regulator of IL-23 in murine macrophages and experimental colitis. J. Immunol. 184:4069-4073.
56. Nava, P., S. Koch, M. G. Laukoetter, W. Y. Lee, K. Kolegraff, C. T. Capaldo, N. Beeman, C. Addis, K. Gerner-Smidt, I. Neumaier, et al. 2010. Interferon-γ regulates intestinal epithelial homeostasis through converging β-catenin signaling pathways. Immunity 32:392-402.
57. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749-795.
58. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
59. Gough, D. J., D. E. Levy, R. W. Johnstone, and C. J. Clarke. 2008. IFNγ signaling: does it mean JAK-STAT? Cytokine Growth Factor Rev. 19:383-394.